The Italian Journal of Pediatrics/Italian journal of pediatrics,
Год журнала:
2024,
Номер
50(1)
Опубликована: Фев. 8, 2024
Delirium,
a
form
of
acute
cerebral
dysfunction,
is
common
complication
postoperative
cardiac
surgery
in
children.
It
strongly
associated
with
adverse
outcomes,
including
prolonged
hospitalization,
increased
mortality,
and
cognitive
dysfunction.
This
study
aimed
to
identify
risk
factors
incidence
delirium
after
children
facilitate
early
identification
provide
reference
for
the
implementation
effective
prevention
management.
A
systematic
literature
search
was
conducted
PubMed,
Web
Science,
Embase,
Cochrane
Library,
Scopus,
CNKI,
Sinomed,
Wanfang
studies
published
English
or
Chinese
from
inception
each
database
November
2023.
The
PRISMA
guidelines
were
followed
all
phases
this
review.
Risk
Bias
Assessment
Nonrandomized
Studies
tool
used
assess
methodological
quality.
total
twelve
included
analysis,
four
classified
as
overall
low
bias,
seven
moderate
one
high
bias.
reported
39
possible
predictors
delirium,
categorized
into
broad
groups:
intrinsic
parent-related
factors,
disease-related
treatment-related
clinical
scores
laboratory
parameters.
By
conducting
qualitative
synthesis
quantitative
meta-analysis,
we
identified
two
definite
32
unclear
related
delirium.
Definite
age
mechanical
ventilation
duration.
Possible
developmental
delay,
cyanotic
heart
disease,
cardiopulmonary
bypass
time,
pain
score.
With
only
few
high-quality
currently
available,
well-designed
more
extensive
prospective
are
still
needed
investigate
affecting
explore
strategies
high-risk
Anesthesiology,
Год журнала:
2012,
Номер
116(6), С. 1312 - 1322
Опубликована: Май 1, 2012
Systemic
α2
agonists
are
believed
to
reduce
pain
and
opioid
requirements
after
surgery,
thus
decreasing
the
incidence
of
opioid-related
adverse
effects,
including
hyperalgesia.The
authors
searched
for
randomized
placebo-controlled
trials
testing
systemic
administrated
in
surgical
patients
reporting
on
postoperative
cumulative
consumption
and/or
intensity.
Meta-analyses
were
performed
when
data
from
5
or
more
100
could
be
combined.Thirty
studies
(1,792
patients,
933
received
clonidine
dexmedetomidine)
included.
There
was
evidence
morphine-sparing
at
24
h;
weighted
mean
difference
-4.1
mg
(95%
confidence
interval,
-6.0
-2.2)
with
-14.5
(-22.1
-6.8)
dexmedetomidine.
also
a
decrease
intensity
-0.7
cm
(-1.2
-0.1)
10-cm
visual
analog
scale
-0.6
(-0.9
-0.2)
The
early
nausea
decreased
both
(number
needed
treat,
approximately
nine).
Clonidine
increased
risk
intraoperative
harm,
nine)
hypotension
20).
Dexmedetomidine
bradycardia
three).
Recovery
times
not
prolonged.
No
trial
reported
chronic
hyperalgesia.Perioperative
consumption,
intensity,
nausea.
Common
effects
arterial
hypotension.
impact
hyperalgesia
remains
unclear
because
valid
lacking.
Journal of Anaesthesiology Clinical Pharmacology,
Год журнала:
2013,
Номер
29(4), С. 496 - 496
Опубликована: Янв. 1, 2013
Background:
Various
adjuvants
are
being
used
with
local
anesthetics
for
prolongation
of
intraoperative
and
postoperative
analgesia.
Dexmedetomidine,
the
highly
selective
2
adrenergic
agonist
is
a
new
neuraxial
adjuvant
gaining
popularity.
Settings
Design:
The
study
was
conducted
in
prospective,
double
blind
manner.
It
included
120
American
Society
Anesthesiology
(ASA)
class
I
II
patients
undergoing
lower
limb
surgery
under
spinal
anesthesia
after
approval
from
hospital
ethics
committee
written
informed
consent
patients.
Materials
Methods:
were
randomly
allocated
into
four
groups
(30
each).
Group
BS
received
12.5
mg
hyperbaric
bupivacaine
normal
saline,
group
BF
25
g
fentanyl,
BC
supplemented
30
clonidine,
BD
plus
5
dexmedetomidine.
onset
time
to
reach
peak
sensory
motor
level,
regression
block,
hemodynamic
changes,
side
effects
recorded.
Results:
Patients
had
significantly
longer
block
times
than
Groups
BC,
BF,
having
comparable
duration
block.
mean
two
segment
147
±
21
min
BD,
117
22
119
23
102
17
(P
>
0.0001).
modified
Bromage
zero
(0)
275
25,
199
26,
196
27,
161
20
BS,
respectively
T8
dermatome
3
not
different
between
groups.
Dexmedetomidine
showed
less
delayed
requirement
rescue
analgesic.
Conclusions:
Intrathecal
dexmedetomidine
associated
prolonged
stability,
reduced
demand
analgesics
24
h
as
compared
or
lone
bupivacaine.
Frontiers in Neuroscience,
Год журнала:
2020,
Номер
14
Опубликована: Май 5, 2020
Dexmedetomidine
is
a
new-generation,
highly
selective
α2
adrenergic
receptor
agonist
with
large
number
of
advantages,
including
its
sedative
and
analgesic
properties,
ability
to
inhibit
sympathetic
nerves,
reduced
anesthetic
dosage,
hemodynamic
stability,
mild
respiratory
depression
abilities
improve
postoperative
recognition.
Its
safety
effectiveness,
as
well
provide
certain
degree
comfort
patients,
make
it
useful
adjuvant
for
wide
range
clinical
applications.
For
example,
dexmedetomidine
commonly
used
in
patients
undergoing
general
anesthesia,
also
exerts
effects
during
tracheal
intubation
or
mechanical
ventilation
intensive
care
unit
patients.
In
recent
years,
the
deepening
research
on
dexmedetomidine,
drug
still
applied
treatment
spastic
pain,
myofascial
neuropathic
complex
pain
syndrome
chronic
headache
multimodal
analgesia.
However,
we
must
note
that
appropriateness
patient
dose
selection
should
be
given
attention
when
using
this
drug;
furthermore,
observed
adverse
reactions
such
hypotension
bradycardia.
Therefore,
effectiveness
long-term
use
remain
studied.
addition,
basic
experimental
studies
have
found
can
protect
important
organs,
brain,
heart,
kidney,
liver
lung,
through
various
mechanisms,
anti-sympathetic
effects,
inhibition
apoptosis
oxidative
stress
reduction
inflammatory
response.
Moreover,
neuroprotective
properties
received
most
from
scholars.
Hence,
review,
mainly
focus
characteristics
applications
especially
role
nervous
system
relief
pain.
Pain and Therapy,
Год журнала:
2016,
Номер
5(1), С. 63 - 80
Опубликована: Фев. 10, 2016
Dexmedetomidine
(Dex)
has
sedative,
analgesic,
and
anesthetic-sparing
effects.
This
meta-analysis
examines
demonstrated
intraoperative
postoperative
effects
of
Dex
administration
during
pediatric
surgery.A
search
for
randomized
placebo-controlled
trials
was
conducted
to
identify
clinical
examining
use
in
children,
infants,
neonates.
Primary
outcome
opioid
consumption;
secondary
outcomes
were:
pain
intensity
nausea
vomiting
(PONV).Fourteen
controlled
performed
painful
procedures
were
analyzed.
Intraoperative
associated
with
significantly
reduced
consumption
the
postanesthesia
care
unit
[PACU;
risk
ratio
(RR)
=
0.31
(0.17,
0.59),
I
(2)
76%,
p
<
0.0001
cumulative
z
score
using
trial
sequential
analysis],
decreased
PACU
[standardized
mean
difference
(SMD)
-1.18
(-1.88,
-0.48),
91%,
0.0001]
but
had
no
effect
upon
PONV
incidence
[RR
0.67
(0.41,
1.08),
0%,
0.48].
Subgroup
analyses
found
administering
adenotonsillectomy
a
bolus
<0.5
µg/kg
(irrespective
continuous
administration)
without
on
studies
outcomes.
Heterogeneity
high
among
results
suspicion
publication
bias
present
all
analyzed
outcomes.This
shows
that
children
reduces
opioids
PACU.
According
our
results,
optimal
dose
be
≥0.5
µg/kg.
Future
have
explore
this
particular
point
analgesic
longer
periods.